FNDC3A and Miyoshi myopathy: Given that FNDC3A is also mutated in a fraction of MM patients [6] and that its expression was shown to be associated with sensitivity to anti-cancer drugs in MM cell lines [17], here we tested if FNDC3A could have a role in FAM46C-induced sensitization to PF-543 administration.